Skip to main content


Expert Insights: Ensuring Adequate Racial and Ethnic Representation in Amyloidosis Clinical Trials

Dr. Frederick Ruberg, cardiologist at the Boston University Amyloidosis Center, discusses the diversity of racial and ethnic occurrences of amyloidosis, and why this should parallel patient representation in clinical trials. He illustrates the persistent disparities observed by race and ethnicity and how un-recognized ATTR amyloidosis, for example, could be contributing to such differences. Adding more evidence, he shares how published clinical trials of ATTR-CM agents are insufficiently diverse. He summarizes possible solutions for improving future clinical trial participation.

Expert Insights: Racial and Ethnic Disparities in Cardiac Amyloidosis

Dr. Michelle Kittleson from Cedars-Sinai discusses the five domains defining the social determinants of health. She explores how these domains can have direct and indirect effects on the health and well being health outcomes. Her presentation looks at cardiac amyloidosis through the lens of these domains, which is important for cardiologists to understand in order to diagnose, treat, and care for patients.

This website uses cookies

This site uses cookies to provide more personalized content, social media features, and ads, and to analyze our traffic. We might share information about your use of our site with our social media, advertising, and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. We will never sell your information or share it with unaffiliated entities.

Newsletter Icon